- 2 Benbow EW. Medical students' views on necropsies. *J Clin Pathol* 1990;43:969-76.
- 3 Benbow EW. Why show autopsies to medical students? *J Pathol* 1990;162:187-8.
- 4 Benbow EW. The attitudes of second- and third-year medical students to the autopsy. A survey by postal questionnaire. *Arch Pathol Lab Med* (in press).
- 5 Anderson RE, Hill RB. Epitome. The current status of the autopsy in academic medical centers in the United States. *Am J Clin Pathol* 1989;92:s31-s7.
- 6 Hill RB, Anderson RE. *The Autopsy: medical practice and public policy*. Stoneham, Massachusetts: Butterworths, 1988:67-90.
- 7 Anderson RE, Hill RB, Key CR. The sensitivity and specificity of clinical diagnostics during five decades: toward an understanding of necessary fallibility. *JAMA* 1989;261:1610-7.

Defective erythropoiesis in myelodysplastic syndromes

We read with interest the report of Williamson *et al* describing uncommon cases of red cell aplasia (RCA) in patients with myelodysplastic syndromes (MDS).¹ The mechanism of RCA in their first three cases was attributed to an intrinsic defect of maturation and proliferation of erythroid precursors occurring as part of the myelodysplastic disorder, whereas in the second three cases a different, and possibly autoimmune aetiology, was suggested. We believe that cytogenetic and molecular study of such unusual cases is important. Most cases of MDS and other malignant haematological disorders are associated with structural chromosomal abnormalities. Cytogenetic study of unusual cases with common features, such as these cases of RCA, might indicate a common chromosomal abnormality which would point to the existence of genes which encode key regulators of erythroid lineage development at or near the junction of the chromosomal aberration. The key regulators of lineage commitment and differentiation in haemopoiesis remain unknown, and an investigative approach through the study of nature's genetic errors might lead to their discovery.

Using such an approach we have recently described a possible association between defective erythropoiesis and an abnormality of chromosome 11.² A case of primary myelofibrosis was identified which showed morphological erythroid aplasia and absent circulating erythroid progenitors. The patient had greatly increased numbers of circulating granulocyte-monocyte progenitor cells (CFU-GM). Co-culture of peripheral blood mononuclear cells with irradiated allogeneic normal bone marrow stroma generated increased numbers of CFU-GM compared with controls but failed to generate erythroid progenitors, providing further evidence for an intrinsic defect in erythropoiesis. Our patient exhibited a previously unreported complex karyotype. Only once previously has the absence of erythroid progenitors in primary myelofibrosis been studied in relation to cytogenetic abnormalities, and this case also indicated a complex karyotype which shared with our case a defect on chromosome 11. The abnormality in our case was 11q— with the break point at 11q13. A literature review showed that the proto-oncogene SEA (S13 avian erythroblastosis oncogene homolog) maps to the 11q13 region and we intend to study the possible role of this gene at the molecular level.

WN PATTON
Department of Haematology, The Medical School
University of Birmingham B15 2TT
CM BUNCE
G BROWN
Department of Immunology, The Medical School
University of Birmingham B15 2TT
S LARKIN
Department of Cytogenetics, Birmingham Maternity
Hospital, Birmingham B15 2TH

- 1 Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. *J Clin Pathol* 1991;44:431-2.
- 2 Patton WN, Bunce CM, Larkin S, Brown G. Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality. *Br J Cancer* 1991;64:128-31.

Drs Williamson *et al* comment:

The case cited above is certainly of interest in investigating the pathogenesis of red cell aplasia in myelodysplasia (MDS). The overlap of morphological features between MDS and myelofibrosis is increasingly being recognised,¹ and it would be intriguing to know the consequences at the gene level in this case of 11q— with break point at 11q13.

Our cases all had attempted cytogenetic analysis of marrow aspirate. Four gave a normal karyotype and two failed to yield metaphases. Several of our cases date from the early 1980s and the cytogenetic technique has undoubtedly improved since then. Our rate of clonal cytogenetic abnormality in MDS in the Wessex region is about 35-40% which accords with the national average. A few published series quote clonal abnormality rates of 75% plus, but these may be the result of repeated analysis of large numbers of cells and may be influenced by case selection. In the Wessex region we have never encountered the 11q13 region as being involved in a case of MDS. The 1988 Catalogue of Chromosomal Aberrations in Cancer² lists only five reported cases where the 11q13 region has been involved in myelodysplastic/proliferative disorders, often as part of a complex karyotype. A review of the other published cases of MDS and red cell aplasia referenced in our paper shows that all five in which cytogenetics are reported yielded a normal karyotype. Thus although of some interest, it remains to be seen if the 11q13 region has a role in the regulation of erythropoiesis.

- 1 Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. *Br J Haematol* 1991;78:161-6.
- 2 Mittleman F. *Catalogue of chromosomal aberrations in cancer*. 3rd edn. New York: Alan R Liss, 1988.

Visceral leishmaniasis in human immunodeficiency virus disease

I read the very interesting article by Curry, Turner, and Lucas.¹ It is important to include visceral leishmaniasis (VL) as an opportunistic protozoan infection in patients infected with HIV, as it is common in endemic areas.² Although the authors comment on some of the salient diagnostic and therapeutic features of VL in patients with HIV, the description is perhaps incomplete as it is based on only a few cases. Over the past few years, most cases of VL in HIV infection have been reported from Spain, probably due to a high incidence of

both VL and HIV infection and a greater awareness about this association once the first few cases had been described. In 1990 two independent studies described the features of VL in many cases of HIV.^{2,3} More recently, our cooperative multicentre study of 40 patients, including most cases that had appeared in Spain up to the beginning of 1990, has updated that experience.⁴

Although in some patients VL can be the consequence of reactivated disease, the finding that 92.5% of the patients were intravenous drug misusers suggested that the disease could be transmitted intravenously (which is an occasional route of transmission in immunocompetents). VL can occur at all stages of HIV infection, but 77% of patients were classified as stage IV with CD4 counts below $4 \times 10^9/l$, suggesting that it is commoner in the later stages of HIV infection. Most patients present with a clinical picture of "classic" Kala-azar with fever, hepatosplenomegaly, and pancytopenia, but some are asymptomatic and are diagnosed incidentally. In all patients *Leishmania amastigotes* were demonstrated in the bone marrow smear, and in the liver of 94.5% of the patients who had a biopsy. In four cases *L. amastigotes* were found in normal skin, and were also present in skin lesions of a Kaposi's sarcoma in one case. This is not a surprising finding, as *L. amastigotes* are found in normal skin in immunocompetent patients with VL. The two most remarkable findings were the absence of leishmanial antibodies, present in only 35.2% of cases, and the chronic relapsing course of the disease. Although 75% of patients had a good initial response to antimony drugs, 42.5% followed a chronic or relapsing course; 40% of patients died due to HIV related causes, and death was only inadvertently related to the relapsing course of the disease.

These findings suggest that VL behaves like other infections in HIV seropositive patients, such as tuberculosis or *Pneumocystis carinii*, showing a good response to initial treatment but persisting as latent chronic disease. Conventional treatment with antimony is not effective in half the patients and other therapeutic approaches are needed. Production of α -interferon (α -INF) and other lymphokines are essential to activate macrophages, but these are defective in both VL and HIV infections. Adjuvant treatment with γ -INF has been effective in animals, in experimental models of human macrophages, and in refractory VL in immunocompetent patients.⁵ These results suggest that γ -INF could also be effective in VL in HIV seropositive patients and a therapeutic trial is currently being conducted in Spain.

VL is an opportunistic infection in HIV seropositive patients that is found increasingly often. It must be suspected and precluded in patients presenting with fever, hepatosplenomegaly, and pancytopenia, and even in less ill patients living in or travelling to endemic areas.

C MONTALBAN
Ministerio de Sanidad y Consumo,
Instituto Nacional de la Salud,
Hospital Ramon y Cajal,
Carretera de Colmenar,
Madrid 28034
Spain

- 1 Curry A, Turner AJ, Lucas S. Opportunistic protozoan infections in human immunodeficiency virus disease: Review highlighting diagnostic and therapeutic aspects. *J Clin Pathol* 1991;44:182-93.

- Montalban C, Martinez-Fernandez R, Calleja JL, *et al.* Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. *Rev Infect Dis* 1989;11:655-60.
- Berenguer J, Moreno S, Cercenado E, Bernaldo de Quiros JCL, Garcia de la Fuente A, Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). *Ann Intern Med* 1989;111:129-32.
- Montalban C, Calleja JL, Erice A, *et al.* Visceral Leishmaniasis in patients infected with human immunodeficiency virus. *J Infect* 1990;21:261-70.
- Badaró R, Falcoff E, Badaró FS, *et al.* Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. *N Engl J Med* 1990;322:16-21.

Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma

Lawlor and colleagues have reported a case of persistent polyclonal B lymphocytosis (PPBL) and subsequent malignant pulmonary blastoma and suggest a possible aetiological role for Epstein-Barr virus (EBV).¹ This conclusion was based on a single EBV viral capsid antigen (VCA), IgG titre of 1/1280, for which the method was not given. We cannot agree with this conclusion.

EBV antibody titres are usually measured by indirect immunofluorescence and a great deal has been published which describes this serological screening in normal persons and patients with EBV related diseases. Antibodies to EBV are present in most adults worldwide.² The extent of antibody responses to EBV antigens varies with age and immune function, with the prevalence of high antibody titres increasing with age in healthy persons.³ Overrepresentation of high titres of VCA specific IgG antibodies, compared with appropriate controls, has been observed in a large variety of non-malignant and malignant diseases.² Patients with the EBV associated malignancies, such as Burkitt's lymphoma and nasopharyngeal carcinoma (NPC), have substantially higher titres and a broader spectrum of antibodies to EBV determined antigens. Titres obtained in various laboratories are not always directly comparable and it is unfortunate that the method was not given in Lawlor's study.

Results obtained in our laboratory of EBV serology in various patient groups are presented in the table. Although the geometric mean titres of anti-EBV VCA IgG are higher in infectious mononucleosis and NPC, where EBV has a specific and well documented role, it is clear from the considerable overlap in the range of titres in all groups that individual measurement is a poor indicator of EBV disease. It is thus unacceptable to use a single titre of antibodies to any one antigen as a basis for implicating EBV.

The profile of antibody response to a range of EBV antigens is more reliable and may

assist in identifying potential aetiological roles for the virus.

In Lawlor's case report a role for Epstein-Barr virus in the pathogenesis of PPBL and malignant pulmonary blastoma has not been adequately established.

We agree with Sumaya⁴ that there is an urgent need for a collaborative effort by diagnostic and research laboratories to standardise the limits of "normal" EBV serological responses.

DE WYATT
PV COYLE
*Regional Virus Laboratory,
Royal Victoria Hospital,
Grosvenor Road,
Belfast BT12 6BN.*

- Lawlor E, Murray M, Sullivan F, *et al.* Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma. *J Clin Pathol* 1991; 44:341-2.
- Henle W, Henle G. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. *The Epstein-Barr virus*. New York: Springer-Verlag, 1979:61-78.
- Schmader KE, van der Horst CM, Klotman ME. Epstein-Barr virus and the elderly host. *Rev Infect Dis* 1989;11:64-73.
- Sumaya CV. Epstein-Barr virus serologic testing: diagnostic indications and interpretations. *Pediatr Infect Dis* 1986;5:337-42.

Dr Lawlor comments:

I fully agree with Wyatt and Coyle that there may be considerable overlap between EBV titres in a variety of conditions and that a wider antibody profile to EBV antigens where available is desirable. I would also support their comments on the necessity of standardisation of methods of EBV serology, particularly immunofluorescence, the method used in this case.

A number of apparently normal subjects can have a raised IgG VCA titre for some years after infectious mononucleosis.¹ In this particular patient, a middle aged woman with a benign lymphoproliferative disorder who subsequently developed a rare pulmonary tumour, the occurrence of a raised titre IgG VCA in the absence of evidence of generalised non-specific immune stimulation² (CMV 1/8, herpes 1/32, Toxoplasma (1 gM) 1/64 and IgG titres at the lower limit of normal), while not a definite indicator of EBV disease, suggest that the role of EBV should be considered in the aetiology of one or both of these conditions.

- Horwitz CA, Henle W, Henle G, Rudnick H, Latts E. Long term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. *J Infect Dis* 1985;151:1150-3.
- Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky MPH, Schonberger LB. A cluster of patients with a chronic mononucleosis-like syndrome. *JAMA* 1987;257:2297-307.

BOOK REVIEWS

All titles reviewed here are available from the BMJ Bookshop, PO Box 295, London WC1H 9TE. Prices include postage in the United Kingdom and for members of the British Forces Overseas, but overseas customers should add £2 per item for postage and packing. Payment can be made by cheque in sterling drawn on a United Kingdom bank, or by credit card (Mastercard, Visa or American Express) stating card number, expiry date, and your full name.

Markers for Neural and Endocrine Cells. Molecular and Cell Biology, Diagnostic Applications. Ed M Gratzl, K Langley. (Pp 222; 48 figs; £67.) VCH. 1991. ISBN 3-527-28167-3.

It is a stated hope of the editors that the book should act as a bridge between fundamental research workers and clinicians by reviewing the latest data on the molecular biology, biochemistry and cell biology of various marker proteins for neural and endocrine cells. In large measure this has been achieved by uniformity of style and presentation which have made the text attractive to both basic scientists and clinicians. The usefulness of this book is greatly enhanced by a liberal number of illustrations and a list of relevant up to date references.

For those who have a particular interest in the relation between the nervous and endocrine systems, this book is to be recommended.

This multi-author book comprises seven chapters divided into three main sections: ontogenetic relations; molecular and cell biology; and applications of marker substances useful for characterising neurones and endocrine cells.

While neurones and endocrine cells share many properties they also differ in important respects (chapter 1). For example, they do not all share a common embryological origin from the ectodermal germ layer: examples include the endocrine cells associated with the digestive tract.

Further characterisation of membrane proteins of synaptic vesicles has allowed major progress to be made in the understanding of the biogenesis and life cycles of the various types of synaptic vesicle and the development of new concepts for neuronal secretion in the context of established pathways of exocytosis in other cells (chapter 2).

Chapter 3 reviews the biochemical, cell biological, and molecular biological features of neuroendocrine granules, and the immunohistochemical data of these proteins are summarised and compared in normal and human tumours of neuroendocrine cells.

Chapter 4 concentrates on aspects of cellular expression and describes the likely functions of a family of related glycoproteins collectively known as neural cell adhesion molecules (NCAM). It is now apparent that NCAM is not confined in adults to neurones

Titres of anti-EBV VCA IgG antibody in four patient groups

Patient group (n =)	Geometric mean titre	Titre range
Infectious mononucleosis (21)	353.3	80-10,240
Other suspected viral illnesses (29)	232.7	<10- 1280
NPC (35)	1358.3	160-10,240
Other head and neck tumours (19)	297.5	20- 5120